Diseño de un modelo poblacional para la monitorización farmacocinética de infliximab en enfermedad inflamatoria intestinal

  1. FRAILE OLEAGA, Sofia 1
  2. SANCHEZ-HERNANDEZ, José Germán 1
  3. PEREZ_BLANCO, Jonás Samuel 1
  4. CALVO, María Victoria 1
  1. 1 Facultad de Farmacia, Universidad de Salamanca. Campus Miguel de Unamuno.
Journal:
Farmajournal

ISSN: 2445-1355

Year of publication: 2018

Volume: 3

Issue: 1

Pages: 77-85

Type: Article

More publications in: Farmajournal

Sustainable development goals

Abstract

Anti-TNF medications have revolutionized the treatment of inflammatory bowel disease improving the symptomatology and the progress of the disease, influencing all this in the patient’s quality of life. The individual response of infliximab may be influenced by his pharmacokinetic and immunogenicity so that therapeutic concentration monitoring of the drug can guide this biologic treatments. However, there is great controversy because there is still no clear consensus in defining the therapeutic range and the most appropriate time for the performance of monitoring. The aim of this study is to justify the pharmacokinetic monitoring of infliximab and to design a preliminary population model for the monitoring and pharmacokinetic individualization of the drug in patients with inflammatory bowel disease.

Bibliographic References

  • Barlow NL, Mohammed P, Berg JD. Serum trough infliximab and anti-infliximab antibodies in a cohort of gastroenterology and rheumatology patients infliximab therapeutic drug monitoring. Ann Clinical Biochem. 2015;53(4):477-484.
  • Chang J, Girgis L. Clinical use of anti- TNF-a biological agents. A guide for GPs. Aust Fam Physician. 2007;36(12):1035-8.
  • Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65(12):1211–28.
  • Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J ClinPharmacolTher. 2010;48(05):297-308.
  • Felice C, Marzo M, Pugliese D, Papa A, Rapaccini GL, Guidi L, et al. Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases. Expert Opin Biol Ther [Internet]. 2015;15(8):1107–17.
  • Marcela L, Garduño B, Carlos J, Salvador N, Molina HL, Carmen M, et al. Artículo de revisión La farmacocinética poblacional y su importancia en la terapéutica. 2011;27(4):370–7.
  • Radstake, T. R., M. Svenson, A. M. Eijsbouts, F. H. van den Hoogen, C. Enevold, P. L. van Riel, and K. Bendtzen. 2009. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann.Rheum.Dis. 68:1739-1745.
  • VandeCasteele N, Khanna R, Levesque B, et al.The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2014;64(10):1539-1545.
  • VandeCasteele N, Ferrante M, Van Assche G, et al. Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease. Gastroenterology. 2015;148(7):1320-1329.e3.
  • VandeCasteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice. J Clin Pharm. 2015;55(S3):S39-S50.
  • Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease: Results from a pilot Observational Study. Inflamm Bowel Dis [Internet]. 2014;0(0):2014. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00054725-201411000-00011
  • Vaughn BP, Sandborn WJ, Cheifetz AS. Biologic Concentration Testing in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21(6):1435–42.
  • Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013 Feb;72(2):165-78.